Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

1 st -Line Treatment with R-CHOP-14 or R-CHOP-21 in Patients with High-Grade Non-Hodgkin’s Lymphoma Is Similarly Effective: Data from the German Prospective TLN Registry

Wolfgang Knauf, MD PhD, Wolfgang Abenhardt, MD, Johannes Mohm, MD, Jacqueline Rauh, MD, Renate Grugel, Johanna Harde, Martina Jänicke, PhD, Norbert Marschner, MD

Blood (2014) 124 (21): 4406.

https://doi.org/10.1182/blood.V124.21.4406.4406

Published: 2014

Journal Articles

Response To 1 st -Line Treatment With BR Or R-CHOP In Patients With Indolent Non-Hodgkin’s Lymphoma: First Outcome Data From The German Prospective TLN Registry

Wolfgang Knauf, MD, Wolfgang Abenhardt, MD, Richard Hansen, MD, Renate Grugel, Johanna Harde, Norbert Marschner, MD

Blood (2013) 122 (21): 3036.

https://doi.org/10.1182/blood.V122.21.3036.3036

Published: 2013

Journal Articles

Response To 1 st -Line Treatment With BR Or FCR In Patients With Chronic Lymphocytic Leukaemia: First Outcome Data From The German Prospective TLN Registry

Wolfgang Knauf, MD, Wolfgang Abenhardt, MD, Erik Engel, Renate Grugel, Johanna Harde, Norbert Marschner, MD

Blood (2013) 122 (21): 4181.

https://doi.org/10.1182/blood.V122.21.4181.4181

Published: 2013

Journal Articles

Bendamustine Replaces Chlorambucil As “Standard of Care” in the Treatment of Elderly Patients with Chronic Lymphocytic Leukemia in German Hematology Outpatient Centres

Wolfgang Ulrich Knauf, MD, Wolfgang Abenhardt, MD, Arnd Nusch, MD, Renate Grugel, Norbert Marschner, MD

Blood (2012) 120 (21): 4605.

https://doi.org/10.1182/blood.V120.21.4605.4605

Published: 2012

Journal Articles

Non-Interventional Study Hexafil: G-CSF Use in Accordance to Guidelines?

Hans Tesch, MD, Wolfgang Abenhardt, MD, Lutz Dietze, MD, DeLi Tilly Chang, PhD, Bertram Ottillinger, MD

Blood (2012) 120 (21): 2057.

https://doi.org/10.1182/blood.V120.21.2057.2057

Published: 2012

Journal Articles

Bendamustine-Rituximab (BR) Replaces R-CHOP As “Standard of Care” in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres

Wolfgang Ulrich Knauf, MD, Wolfgang Abenhardt, MD, Arnd Nusch, MD, Renate Grugel, Norbert Marschner, MD

Blood (2012) 120 (21): 3666.

https://doi.org/10.1182/blood.V120.21.3666.3666

Published: 2012

Journal Articles

How to Treat Chronic Lymphocytic Leukemia? Data From a Clinical Registry by Office-Based Hematologists in Germany (TLN Registry)

Wolfgang Knauf, MD, Wolfgang Abenhardt, MD, Ali Aldaoud, MD, Christian Lerchenmüller, MD, Michaela Koska, Norbert Marschner, MD

Blood (2011) 118 (21): 4606.

https://doi.org/10.1182/blood.V118.21.4606.4606

Published: 2011

Journal Articles

Early and Risk-Adapted Therapy with Fludarabine in High-Risk Binet Stage A CLL Patients Prolongs Progression Free Survival but Not Overall Survival: Results of the CLL1 Protocol of the German CLL Study Group (GCLLSG).

Manuela A. Bergmann, MD, Barbara F. Eichhorst, MD, Raymonde Busch, Hartmut Doehner, MD, Ursula Vehling-Kaiser, MD, Wolfgang Abenhardt, MD, Michael Hallek, MD, GCLLSG

Blood (2007) 110 (11): 2038.

https://doi.org/10.1182/blood.V110.11.2038.2038

Published: 2007

Journal Articles

Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Carmen D. Schweighofer, MD, Matthias Ritgen, MD, Sebastian Boettcher, MD, Elena Scharf, Barbara F. Eichhorst, MD, Raymonde Busch, Wolfgang Abenhardt, MD, Michael Kneba, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)

Blood (2007) 110 (11): 2053.

https://doi.org/10.1182/blood.V110.11.2053.2053

Published: 2007

Journal Articles

Analysis of the V617F Mutation of the JAK2- and the W515 Mutation of the MPL Gene in Patients with Chronic Myeloproliferative Disease (CMPD) Treated in an Outpatient Practice.

Peter Bojko, MD, Wolfgang Abenhardt, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD

Blood (2007) 110 (11): 4631.

https://doi.org/10.1182/blood.V110.11.4631.4631

Published: 2007

NARROW

1 st -Line Treatment with R-CHOP-14 or R-CHOP-21 in Patients with High-Grade Non-Hodgkin’s Lymphoma Is Similarly Effective: Data from the German Prospective TLN Registry

Response To 1 st -Line Treatment With BR Or R-CHOP In Patients With Indolent Non-Hodgkin’s Lymphoma: First Outcome Data From The German Prospective TLN Registry

Response To 1 st -Line Treatment With BR Or FCR In Patients With Chronic Lymphocytic Leukaemia: First Outcome Data From The German Prospective TLN Registry

Bendamustine Replaces Chlorambucil As “Standard of Care” in the Treatment of Elderly Patients with Chronic Lymphocytic Leukemia in German Hematology Outpatient Centres

Non-Interventional Study Hexafil: G-CSF Use in Accordance to Guidelines?

Bendamustine-Rituximab (BR) Replaces R-CHOP As “Standard of Care” in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres

How to Treat Chronic Lymphocytic Leukemia? Data From a Clinical Registry by Office-Based Hematologists in Germany (TLN Registry)

Early and Risk-Adapted Therapy with Fludarabine in High-Risk Binet Stage A CLL Patients Prolongs Progression Free Survival but Not Overall Survival: Results of the CLL1 Protocol of the German CLL Study Group (GCLLSG).

Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).

Analysis of the V617F Mutation of the JAK2- and the W515 Mutation of the MPL Gene in Patients with Chronic Myeloproliferative Disease (CMPD) Treated in an Outpatient Practice.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only